Dopaminergic cells in the retina express the receptor for brain-derived neurotrophic factor (BDNF) (Cellerino and Kohler, 1997). To investigate whether BDNF can influence the development of the retinal dopaminergic pathway, we performed intraocular injections of BDNF during the second or third postnatal week and visualized the dopaminergic system with tyrosine hydroxylase (TH) immunohistochemistry. Both regimens of BDNF treatment caused an increase in TH immunoreactivity in stratum 1 and stratum 3 of the inner plexiform layer (IPL). D2 dopamine receptor immunoreactivity, a presynaptic marker of dopaminergic cells (Veruki, 1996), was also increased in stratum 1 and stratum 3 of the inner plexiform layer. These data suggest that BDNF causes sprouting of dopaminergic fibers in the inner plexiform layer. Other neurochemical systems, for example, the cholinergic amacrine cells, remained unaffected. Similar effects were observed after injections of neurotrophin-3 and neurotrophin-4, but not nerve growth factor.

Analysis of whole-mounted TH-immunolabeled retinae revealed hypertrophy of dopaminergic cells (+41% in soma areas; p < 0.01) and an increase of labeled dopaminergic varicosities in stratum 1 of the IPL (+51%; p < 0.01) after BDNF treatment. The opposite was observed in mice homozygous for a null mutation of the bdnf gene: dopaminergic cells were atrophic (−22.5% in soma areas; p < 0.05), and the density of TH-positive varicosities in stratum 1 was reduced (57%; p < 0.01). We conclude that BDNF controls the development of the retinal dopaminergic network and may be particularly important in determining the density of dopaminergic innervation in the retina.

Key words: neurotrophin; growth factor; retina; inner plexiform layer; amacrine neuron; development; synaptogenesis; BDNF knock-out mouse; Parkinson’s disease

The mammalian retina is probably the region of the vertebrate brain in which local microcircuits have been described best (Sterling, 1990; Wässle and Boycott, 1991; Kolb, 1994). Because detailed knowledge of its organization is available, the retina provides a convenient system for investigating the effects of neurotrophins on the development of specific CNS connections. The morphology and physiology of one specific retinal neuron, the retinal dopaminergic cell, has been described in detail (for review, see Nguyen-Legrós, 1988; Witkowsky and Schütte, 1991). In mammals, dopaminergic cells are a sparse population of wide-field amacrine (and interplexiform cells) that receive input from cone bipolar cells (Hokocz and Mariani, 1987) and extend processes at the border between the inner nuclear layer and the inner plexiform layer (Voigt and Wässle, 1987; Dacey, 1990). Dopaminergic processes establish synapses mostly onto the soma of a specific type of interneuron in the rod pathway, the glycnergic AII amacrine cell (Voigt and Wässle, 1987), and are restricted to the border between the inner plexiform layer and the inner nuclear layer (stratum 1). Dopamine release is increased by light, and this light-induced release of dopamine is believed to play a role in the inhibitory mechanisms underlying light adaptation (Witkowsky and Dearly, 1991). In a previous work, we reported that dopaminergic neurons in the vertebrate retina express the BDNF receptor TrkB (Barbacid, 1994) and suggested that BDNF may act on dopaminergic retinal neurons (Cellerino and Kohler, 1997). The present study tested this hypothesis by examining the...
effects of the four neurotrophins on the development of dopaminergic innervation in the rat retina after intraocular injection. In addition, dopaminergic neurons were examined in mice homozygous for a null mutation of the bdnf gene.

Some of these data were published previously (Cellerino et al., 1997).

### MATERIALS AND METHODS

**BDNF injections.** Rat pups were anesthetized with ether. In pups younger than postnatal day (P) 15, the eyelids were opened gently with a fine forceps. One microgram of human recombinant BDNF, human recombinant NT-3, human recombinant NT-4, or mouse β-NGF (Alomone Laboratories) in 2 μl of 0.1% bovine serum albumin (BSA) in sterile PBS was injected with a fine glass microelectrode through the sclera at the level of the temporal peripheral retina. The other eye received 2 μl of vehicle solution. The whole procedure required only a few minutes and was completed before the animals recovered from the anesthesia. Surgical procedures were performed according to the German law and the guidelines of the Association for Research in Vision and Ophthalmology (ARVO). For the complete list of animals used in the present study see Table I.

<table>
<thead>
<tr>
<th>Species</th>
<th>Age</th>
<th>Exp. group</th>
<th>n</th>
<th>Preparation</th>
<th>Antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>P14</td>
<td>3 x 1 μg BDNF</td>
<td>3</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P16</td>
<td>3 x 1 μg BDNF</td>
<td>2</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P22</td>
<td>3 x 1 μg BDNF</td>
<td>4</td>
<td>Cryosections</td>
<td>TH, ChAT, CAL</td>
</tr>
<tr>
<td>Rat</td>
<td>P22</td>
<td>3 x 0.5 μg BDNF</td>
<td>3</td>
<td>Cryosections</td>
<td>TH, D2</td>
</tr>
<tr>
<td>Rat</td>
<td>P22</td>
<td>3 x 1 μg NGF</td>
<td>3</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P16</td>
<td>3 x 0.5 μg NT-3</td>
<td>3</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P16</td>
<td>3 x 0.5 μg NT-4</td>
<td>3</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P22</td>
<td>3 x 1 μg NT-3</td>
<td>4</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P22</td>
<td>3 x 1 μg NT-4</td>
<td>4</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>Adult</td>
<td>3 x 1 μg BDNF</td>
<td>3</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Rat</td>
<td>P22</td>
<td>3 x 1 μg BDNF</td>
<td>4</td>
<td>Whole-mount</td>
<td>TH</td>
</tr>
<tr>
<td>Mice</td>
<td>P20</td>
<td>bdnf +/-</td>
<td>3</td>
<td>Cryosections</td>
<td>TH</td>
</tr>
<tr>
<td>Mice</td>
<td>P20</td>
<td>bdnf +/-</td>
<td>3</td>
<td>Whole-mount</td>
<td>TH</td>
</tr>
<tr>
<td>Mice</td>
<td>P20</td>
<td>bdnf +/+</td>
<td>3</td>
<td>Whole-mount</td>
<td>TH</td>
</tr>
<tr>
<td>Mice</td>
<td>P20</td>
<td>bdnf +/-</td>
<td>7</td>
<td>Whole-mount</td>
<td>TH</td>
</tr>
<tr>
<td>Mice</td>
<td>P20</td>
<td>bdnf +/-</td>
<td>5</td>
<td>Whole-mount</td>
<td>TH</td>
</tr>
</tbody>
</table>

Overview of animals used in the present study. Treatment with exogenous neurotrophins started 6 d before animals were killed and was repeated every other day to give a total of three injections. Neurotrophins were always injected in 2 μl of vehicle solution. TH, Tyrosine hydroxylase; ChAT, choline acetyl transferase; D2, D2 dopamine receptors; CAL, calretinin.

whole-mount immunohistochemistry. Animals were anesthetized with ether and killed by cervical dislocation. The eyes were enucleated, the anterior chamber was removed, and the eyecups were fixed for 30 min in 2% PFA in PBS. Retinas were dissected out, four radial cuts were made to allow flattening, and the retinæ were fixed at 4°C for 2 hr in 4% PFA in PBS between two microscopic slides with a spacer interposed to prevent damage. Defattening (Versaux-Boiotti and Nguyen-Logrós, 1986) was used to improve antibody penetration. The retinæ were dehydrated in ascending ethanol concentrations (50, 70, 85, 90, 96, and 100%), incubated for 1 hr at room temperature in xylene, rehydrated in a descending alcohol series, and washed three times in PBS. Retinæ were then incubated overnight in 20% NGS in PBS with 0.3% Triton X-100 containing 1:3000 mouse anti-TH (Instar) for 3 d at 4°C with continuous agitation and for 1 d at 4°C in the same buffer containing a 1:1000 dilution of Cy-3 labeled goat anti-rabbit (Rockland Labs) with continuous agitation. Retinæ were mounted flat, with the retinal ganglion cell layer oriented upward, and coverslipped with a 9:1 mixture of glycerol/PBS. The slides were stored at −20°C between examinations.

Morphometric analysis. Labeled cells were counted directly at the microscope with a 20x objective (type I cells) or 40x oil immersion objective (type II cells) using an Olympus AX-70 microscope. For each mouse retina the sample consisted of five fields of 0.4 mm²: one in the center, adjacent to the optic nerve head, and one approximately in the middle of the retinal radius in each retinal quadrant. For each rat retina, the sample consisted of two 0.4 mm² (0.1 mm² for type II cells) fields in each retinal quadrant: one near the retinal center and one approximately at the middle of the retinal radius.

The number of primary dendrites was determined directly at the microscope by examining 20–30 cells for each retina from the same region in which cells had been counted. Care was taken to sample approximately the same number of cells from each retinal quadrant.

Mean cell size was estimated by photographing the cells with a 40x oil immersion objective, projecting them at a final magnification of 1000x, and tracing their outlines. These drawings were scanned and analyzed with NIH Image 1.44. The sampled areas were 1.2–2.2 mm² in mice and 1.6–3.2 mm² in rats.

To quantify the density of TH-immunopositive varicosities, several fields were photographed in the central retina with the focus in stratum 1 using a 40x oil immersion objective with small numerical aperture. In this way, all TH-positive varicosities were contained on a single focal plane. Pictures were printed at a final magnification of 1000x on high-
contrast photographic paper. The sampling area was represented by a box of 10,000–20,000 μm² where labeled varicosities were all contained in the plane of focus. For each retina, four to six of these areas were counted, and at least one area was selected for each retinal quadrant.

All measurements were performed on coded preparations or pictures by researchers who were unaware of their experimental history.

Differences between experimental and control groups were tested statistically with the paired Student's t test (BDNF-treated rats) or unpaired Student's t test, with independent variabilities in the two samples (bndf mutant mice) using Microsoft Excel.

RESULTS

The retinal dopaminergic network in BDNF-treated rats

Dopaminergic neurons first appear in the rat retina between P3 and P5 (Nguyen-Legrós et al., 1983; Mitrofanis et al., 1988). TH-positive fibers innervating stratum 1 of the inner plexiform layer (IPL) are first detected at the beginning of the second postnatal week and progressively grow to form a continuous plexus of innervation that is not completed before the end of the third postnatal week (Mitrofantis et al., 1988). This period (P5–P21) largely corresponds to the phase of synaptogenesis for amacrine neurons in the rat retina (Horsburgh and Sefton, 1987).

We decided to investigate the effects of BDNF on the development of the dopaminergic network during the second or third postnatal week. We injected BDNF (0.5–1 μg) into the eye in rat pups, followed by one additional injection every other day. The other eye received vehicle injections and served as control. The animals were killed on the seventh day. This regimen was suffi-
Figure 2. Effects of BDNF injections on D2 receptor immunoreactivity. To prevent the ventrodorsal gradient of retinal dopaminergic innervation (Nguyen-Legrés, 1988) from confounding interpretation of the data, only pictures obtained from the central retina were compared. A, Control P22 retina. The D2-labeled dopaminergic plexus is indicated by small arrows. The framed box is magnified in the top left corner of the picture to show a detail of the thin, D2-labeled plexus. B, Contralateral retina that received three injections of 0.5 µg of BDNF at P16, P18, and P20. The D2-labeled plexus in stratum 1 is indicated by small arrows; the plexus in stratum 3 is indicated by open arrowheads. The framed box is magnified in the top right corner of the picture. Scale bar, 50 µm.

Figure 3. Effects of BDNF injections on the development of choline acetyl transferase and calretinin immunoreactivity. The sections illustrated in this figure were obtained from the animal whose retinal dopaminergic system is shown in Figure 1C,D. A, Control P22 retina. Choline acetyl transferase immunoreactivity (ChAT) revealed with a monoclonal anti-ChAT antibody. Unspecific reaction of the secondary antibody with blood vessels is indicated by arrowheads. Two bands of ChAT immunoreactivity are clearly visible in the middle of the IPL. B, The retina contralateral to the retina shown in A, which received three injections of 1 µg of BDNF at P16, P18, and P20. No differences are visible. C, Control P22 retina (calretinin immunoreactivity). Three bands of punctate calretinin immunoreactivity are clearly visible in the IPL. Numerous cells are visible in both the INL and GCL. D, The retina contralateral to the retina shown in A, which received three injections of 1 µg BDNF at P16, P18, and P20. No differences are visible. ONL, Outer nuclear layer; INL, inner nuclear layer; IPL, inner plexiform layer. Scale bar, 35 µm.
cient to persistently increase BDNF levels in the retina, as demonstrated by BDNF immunohistochemistry (data not shown). No differences were noticed between animals treated with 1 or 0.5 \( \mu g \) of BDNF.

A first set of rats received the first injection on P8 and were killed on P14 \( (n = 3) \). In accordance with previously published data (Mitrofanis et al., 1988), the retinal dopaminergic system appeared immature in the control retinae at P14. Somata of dopaminergic cells were labeled, but the plexus of dopaminergic fibers localized in stratum 1 (s1) of the IPL, close to the border of the inner nuclear layer (INL), was visibly less dense than in adults (Fig. 1A). In contrast, a continuous, dense dopaminergic plexus was observed in the BDNF-treated retinae (Fig. 1B). In addition to the TH-positive plexus in s1, a more lightly labeled plexus of dopaminergic innervation was observed in the middle of the IPL (s3). Similar effects were observed in two rats that received the first BDNF injection on P10 and were killed on P16 (data not shown).

In a second set of experiments, rat pups \( (n = 4) \) received the first dose of BDNF on P16, and the effects of exogenous BDNF
were examined at P22. At P22, the retinal dopaminergic system is more mature, and a continuous plexus of dopaminergic innervation is visible in s1 (Fig. 1C) (Mitrofanis et al., 1988). In BDNF-treated retinae, this dopaminergic plexus appeared more dense, but the difference between BDNF-injected and control eyes was not as striking as in younger animals. A striking difference was the presence of a continuous, brightly labeled plexus of dopaminergic innervation in s3 of the BDNF-treated retinae (Fig. 1D). In control retinae, some faint labeling was observed in s3 as well; it consisted of thin, sparse, isolated processes with gaps of variable size between one labeled process and the other. S3 labeling was more dense in the dorsal retina and almost absent in the ventral retina, as already described (Nguyen-Legrós, 1988). By contrast, a continuous, brightly labeled band was visible in s3 in BDNF-treated retinae. This labeled band ran without interruption from the dorsal end to the ventral end of the retina.

Some dopaminergic cells in rodents are interplexiform; i.e., in addition to the usual arborization in the IPL, they extend processes vitreally toward the outer plexiform layer (OPL) (Nguyen-Legrós, 1988; Witkowsky and Schütte, 1991). These processes are very sparse in control animals, whereas their number was visibly increased in BDNF-treated animals (not shown). This effect was difficult to quantify, however, and a detailed analysis of the action of neurotrophins on the development of interplexiform cells will be the subject of a future study.

Visible effects were observed in neither the IPL nor the OPL if the same regimen of BDNF intraocular injections was performed in adult animals (n = 3; data not shown).

We also analyzed the expression of D2 dopamine receptors in BDNF-treated retinae. Pharmacological (for review, see Witkowsky and Dearry, 1991) and immunohistochemical studies (Veruki, 1996) have shown that dopaminergic neurons use D2 receptors as presynaptic autoreceptors. Therefore, D2 immunoreactivity provides an independent marker for studying retinal dopaminergic innervation. In control retinae, D2 immunoreactivity is diffusely distributed in the IPL, except that in s1 a very thin row of brighter varicosities standing out against the diffuse labeling of the IPL is seen (Fig. 2A). This band of more intense labeling corresponds to the plexus of dopaminergic innervation (Veruki, 1996). D2 immunoreactivity in s1 is visibly enhanced after BDNF treatment. In addition, a labeled band standing out against the diffuse IPL labeling is faintly visible in s3 (Fig. 2B). There are no apparent changes in the diffuse staining in the IPL. These data are consistent with the idea that BDNF increases the density of dopaminergic terminals.

To test whether an exogenous supply of BDNF disturbs the lamina-specific organization of all neurochemically defined connections in the IPL, we examined immunoreactivity for calretinin and choline acetyl transferase (ChAT) in the same retinae in which changes in the organization of the dopaminergic inner-

**Figure 5.** Effects of BDNF injections on TH immunoreactivity (whole-mount preparations). Focus is at the level of stratum 1, central retina. The cell bodies of TH-positive cells are in the inner plexiform layer and therefore out of focus. A, Control P22 retina. A type I dopaminergic neuron is indicated by a large arrowhead; its dendritic arborization is out of focus. B, The retina contralateral to the retina shown in A that received three injections of 1 μg BDNF at P16, P18, and P20. Type I dopaminergic neurons are indicated by big arrowheads; type II dopaminergic neurons are indicated by small arrowheads. Scale bar, 22 μm.
process can be traced as it ramifies in stratum 3. Scale bar, 35 μm. Figure 6. Detail of the plexus of dopaminergic innervation in stratum 3 in a BDNF-treated retina. A. Focus in stratum 1. Cell bodies of type I dopaminergic cells are indicated by arrowheads. Note the process emerging from the cell at the bottom of the picture (small arrow). In B, the same process can be traced as it ramifies in stratum 3. Scale bar, 35 μm.

Stratum 1

Stratum 3

Quantification of BDNF effects in whole-mount preparations

Dopaminergic neurons are very sparse (usually only two to five cells are visible per section), and it is difficult to quantify cell density and size in radial sections because of the very limited sample size. To provide a quantitative basis for the differences observed in the organization of the dopaminergic network after BDNF injections, rat pups (n = 4) received BDNF by intraocular injections, starting at P16, according to the described protocol. The animals were killed at P22, and BDNF-treated retinae and the contralateral control retinae were processed for whole-mount TH immunohistochemistry.

Generally, two morphological classes of dopaminergic cells can be differentiated in adult mammals: sparse cells with large somata that display intense TH immunoreactivity, and a more numerous population of smaller cells with light TH immunoreactivity. Mariani and Hokoç (1988) named the former type I and the latter type II dopaminergic neurons. Another peculiar characteristic of adult dopaminergic innervation, particularly striking in flat-mount preparations, is its organization into pericellular baskets surrounding the somata of amacrine neurons (mostly glycinergic AII amacrine cells) located at the vitreal border of the INL (Voigt and Wässle, 1987). We observed no type II dopaminergic neurons in one of the flat-mounted P22 retinae obtained from control eyes. In the other three, type II cells were encountered only occasionally. These cells were labeled very weakly, and the cellular contours were not clearly distinguishable. No pericellular baskets were evident at P22 (Fig. 5). Flat-mounted BDNF-treated retinae were visibly different from the control retinae. Type II dopaminergic neurons could be readily seen. In addition, Type I dopaminergic cells appeared hypertrophic; their dendritic arborization was more intensely labeled, and TH-positive varicosities seemed to be more numerous. The presence of a profuse TH-positive plexus in s3 of BDNF-treated retinae was evident in the whole-mount preparation. Processes in s3 could be often traced back to the cell of origin, which was always a type I cell (Fig. 6).

Statistical analysis of morphological parameters in flat-mounted retinae demonstrated significant differences between control and BDNF-treated retinae. The density of labeled type II dopaminergic neurons was increased approximately sixfold (p < 0.001), whereas the density of type I dopaminergic neurons did not change. The soma area of type I dopaminergic neurons was increased by 41% (p < 0.01), and the density of TH-positive varicosities in s1 was increased by 51% (p < 0.01). These quantitative data are summarized in Figure 7. The mean number of primary dendrites also increased from 3 to 3.6 (p < 0.01). The widespread overlap between the dendritic arbors of adjacent type I dopaminergic neurons precluded a more detailed analysis of their dendritic complexity.

The retinal dopaminergic network in bdnf−/− mice

To test whether the effects observed after postnatal treatment with BDNF reflected a physiological action of BDNF on retinal dopaminergic neurons, we analyzed TH immunoreactivity in mice with a targeted deletion of the bdnf gene. Retinae from P20 bdnf−/− mouse pups (n = 5) obtained by crossing bdnf−/− mice were processed for whole-mount TH immunohistochemistry.
Retinae obtained from P20 bdnf+/− (n = 7), bdnf+/+ (n = 3), and bdnf−/− mice (n = 5) were processed in parallel to allow comparison. P20 mouse retinae differed from age-matched rat retinae in that the density of type I dopaminergic neurons was more than double that of the rat, and the density of TH-positive varicosities was almost 10-fold higher (compare Fig. 5 and Fig. 8). However, the general organization of the dopaminergic system was otherwise similar between rats and mice. No type II cells were detected in mice.

No differences between bdnf+/+ and bdnf+/− mice were noticed at a qualitative analysis. In contrast, the dopaminergic system was clearly altered in bdnf−/− mice. The labeling of type I dopaminergic neurons was less intense, and the density of TH-positive varicosities was visibly reduced. A substantial variance in the intensity of TH immunolabeling and in the density of labeled varicosities was observed between the different bdnf−/− mice. Because the intensity of TH immunolabeling varied little among different bdnf+/− and bdnf+/+ mice, and retinae of all three different genotypes were dissected out and processed in parallel, a variability in the efficiency of immunolabeling can be excluded. The variability just mentioned thus likely reflects interindividual differences in phenotype expression.

Morphological parameters of TH-positive cells were quantified in the bdnf+/+ and bdnf−/− mice. bdnf+/− animals were not analyzed, because they did not visibly differ from wild-type controls. The number of TH-positive cells was slightly reduced in bdnf−/− mice (−31%; p < 0.05). The reduction in the number of type I dopaminergic neurons may have resulted from increased cell death or from failure to detect some faintly labeled neurons. The soma area of type I dopaminergic neurons was reduced by 22.5% (p < 0.05), and the density of TH-positive varicosities was reduced by 57% (p < 0.01) (Fig. 9). The densities of TH-positive varicosities were distributed with a much larger SD in the bdnf−/− group than in the control group, probably as a consequence of the phenotype variability mentioned above.

**DISCUSSION**

The present study showed that intraocular injections of BDNF during the second or third postnatal week cause increased TH expression in retinal dopaminergic neurons, hypertrophy of retinal type I dopaminergic neurons, and increased density of TH-positive varicosities in rats. On the other hand, in mice homozygous for a null mutation of the bdnf gene, retinal dopaminergic neurons are atrophic and the density of TH-positive varicosities is reduced.

Upregulation of TH expression was observed also after injection of NT-3 and NT-4 but not NGF. The observation of more that one neurotrophin acting on the same neuron is not surprising: other CNS populations have had similar responsiveness (McAllister et al., 1995, 1997; Meyer-Franke et al., 1995; Oppenheim, 1996). The phenotype of bdnf−/− mice clearly indicates that the effects of exogenously supplied BDNF reflect a physiological action. NT-4 may just activate TrkB that is present on these cells (Cellerino and Kohler, 1997), whereas the role of
NT-3 is less clear, and because data are lacking that refer to nt-32 mice, a pharmacological action cannot be excluded. It is equally possible, however, that also under physiological conditions dopaminergic neurons respond to several factors and that removal of both NT-3 and BDNF would impair their development even more severely.

The effects of BDNF on the dopaminergic neurons in the substantia nigra are well known (Hyman et al., 1994). Retinal and nigral dopaminergic neurons have different embryonic origins, however, and it is interesting that BDNF acts similarly on both of these dopaminergic populations. An interesting characteristic of dopaminergic retinal neurons is their use of GABA as co-neurotransmitter (Wa¨ssle and Chun, 1988); in this sense they are homologous to GABAergic interneurons. Subpopulations of GABAergic interneurons in the cortex and hippocampus express TrkB, respond to BDNF, and are affected in bdnf22 mice (Nawa et al., 1994; Cellerino et al., 1996) (for review, see Marty et al., 1997). Retinal dopaminergic neurons would then be similar to other, telencephalic populations of GABAergic cells in their trophic dependence.

BDNF is known to influence the expression of several phenotypic markers of CNS neurons (Jones et al., 1994; Nawa et al., 1994; Marty et al., 1996). In the retina, BDNF clearly increases the expression of TH, an effect that is particularly visible in type II dopaminergic cells. All of the described effects (increased number of TH-positive varicosities in s1, increased TH labeling in s3) may have resulted from enhanced TH expression rather than from changes in the dopaminergic network. Two lines of evidence argue against this possibility. (1) The changes in TH immunoreactivity are paralleled by changes in the distribution of D2 dopamine receptors, which are present as presynaptic autoreceptors on the processes of retinal dopaminergic neurons (Veruki, 1996). Because expression of these two proteins is likely to be regulated independently, concerted changes in their distribution are strongly indicative of corresponding physical changes in the dopaminergic network. (2) BDNF treatment dramatically increases the density of the TH-positive plexus in s3. When observed in flat mounts, these processes into s3 are seen to originate from type I dopaminergic neurons. The detailed morphology of type I dopaminergic neurons in normal animals is known from intracellular fillings (Voigt and Wässle, 1987; Dacey, 1990), and these cells extend only a few, if any, short processes into s3. For this reason, the profuse s3 labeling observed after BDNF treatment cannot be explained by upregulation of TH immunoreactivity in processes that are present, but not visible, in normal animals and must therefore be the result of sprouting.

Following these two lines of reasoning, it seems also likely that variations in the number of detectable TH-positive varicosities in s1 are also attributable, at least in part, to changes in the physical density of the dopaminergic network.

These data would be in line with a recent report showing that the density of afferent innervation and the size of afferent preganglionic neurons in the sympathetic system are controlled by limited amounts of BDNF produced in their target, the sympathetic neurons (Causing et al., 1997). A further parallel between preganglionic neurons and retinal dopaminergic cells is that both neuronal populations are atrophic in bdnf22 mice and are hypertrophic if excess BDNF is present.
It is a widely accepted view that the density of innervation of peripheral tissues is determined by the amount of target-derived neurotrophic factors. The seminal work of Purves and colleagues (1988) suggested that this concept could be extended to synapses in the nervous system. This view has been supported, although indirectly, by a subsequent series of studies showing effects of neurotrophins on activity-dependent synaptic plasticity (for review, see Lo, 1995; Thoenen, 1995; Bonhoeffer, 1996; Cellerino and Maffei, 1996). The data presented in this paper, combined with results obtained from studies of the sympathetic system (Causing et al., 1997) and the frog visual system (Cohen-Cory and Fraser, 1995), strengthen the hypothesis that the density of innervation in the CNS is controlled by limited amounts of neuron-derived neurotrophic factors.

If BDNF increases the density of dopaminergic innervation, it would be interesting to investigate the specificity of these connections. In the retina, various physiological and neurochemical pathways are segregated into different strata of the IPL. The anatomical segregation of the physiologically defined ON and OFF pathways requires afferent electrical activity (Bodnarenko et al., 1995). The mechanisms underlying the segregation of more finely restricted pathways are totally unknown. It is thus interesting to observe that BDNF, NT-3, and NT-4 all cause a more profuse dopaminergic innervation in s1 and s3 but not in other strata of the IPL. Because a sparse dopaminergic innervation is normally present in s3 (Nguyen-Legrós, 1988), sprouting after neurotrophin treatment occurs only in the strata where growth is permitted under normal conditions. In other words, if molecular cues (attractive/repulsive) are responsible for the radially restricted growth of dopaminergic fibers, this constraint cannot be overcome by neurotrophins. This is consistent with data obtained in the visual cortex and the retinotectal system showing that BDNF influences the tangential organization of afferents but does not perturb the lamina-specific pattern of innervation (Cabrera et al., 1995; Inoue and Sanes, 1996).

In adult mammals, dopaminergic innervation of s1 is organized into pericellular baskets, many of which are formed around the small-field, bistratified AII amacrine cells (Voigt and Wässle, 1987). It would be interesting to investigate whether BDNF is required for the formation of these restricted connections and whether exogenous BDNF perturbs the specificity of these connections. Unfortunately, bdnf−/− mice do not survive long enough to allow this analysis, whereas long-term BDNF treatment over several weeks cannot be obtained by repeated intraocular injections. Therefore, it is presently impossible to answer this interesting question.

Our data clearly indicate that BDNF is essential for the development of the retinal dopaminergic system. It remains to be

---

**Figure 9.** Quantitative analysis of dopaminergic neurons in bdnf+/+ and bdnf−/− mice at P20. A, Density of type I dopaminergic cells expressed as number of cells per square millimeter. See Materials and Methods for details of the sampling method. ++/+ indicates bdnf+/+ mice, and −/− indicates bdnf−/− mice. B, Soma area of type I dopaminergic neurons. See Materials and Methods for details of the sampling method. ++/+ indicates bdnf+/+ mice, and −/− indicates bdnf−/− mice. C, Density of TH-positive varicosities in stratum l of the inner plexiform layer expressed as number of varicosities per square millimeter. See Materials and Methods for details of the sampling method. ++/+ indicates bdnf+/+ mice, and −/− indicates bdnf−/− mice. Data were analyzed using a two-tailed Student’s t test with independent variability in the two samples. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01. Error bars represent SEM.
determined which type of retinal cells provides BDNF to these neurons. BDNF is expressed by retinal ganglion cells in the rat (Peréz and Caminos, 1995), but dopaminergic amacrine neurons make no direct connections with retinal ganglion cells. The main target of dopaminergic cells is the AII amacrine cell. A low level of BDNF expression has been shown in the INL as well (Peréz and Caminos, 1995; Hallböök et al., 1996) (our unpublished observation), and it has been shown that retinal BDNF mRNA is not dramatically reduced when retinal ganglion cells are eliminated by section of the optic stalk (Herzog and von Bartheld, 1997). Dopaminergic neurons coexpress dopamine and GABA (Wässle and Chun, 1988) and either could obtain BDNF from their postsynaptic targets, as do GABAergic neurons in the visual cortex (Cellerino et al., 1996), or be involved in an autocrine loop, like midbrain dopaminergic neurons (Seroogy et al., 1994). In this context, it is of great interest that attenuation of trkB expression in vivo reduces the expression of parvalbumin in AII amacrine neurons (Rickman and Bowes-Rickman, 1996). The effects observed on AII amacrine cells may be secondary to changes in the dopaminergic network or vice versa. A detailed study of BDNF expression in dopaminergic neurons and AII amacrine cells is indispensable for examining this issue.

REFERENCES


Mitrofanis J, Maslim J, Stone J (1988) Catecholaminergic and cholin-